首页 › 基金 › CAXTON CORP › XFOR
CAXTON CORP 对 XFOR 的持仓历史
X4 PHARMACEUTICALS INC · 医疗保健
CAXTON CORP 在 Q2 2026 的 13F 申报中披露持有 XFOR(X4 PHARMACEUTICALS INC)15,557 股,市值约 US$73K,约占其申报组合的 3.92%,在其申报持仓中市值排名第 8 位。 CAXTON CORP 最近 3 个申报季度中有 3 个季度披露了 XFOR 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
CAXTON CORP 对 XFOR 的持仓演变
CAXTON CORP 于 Q4 2025 首次披露 XFOR 持仓:15,557 股(约 US$62K)。 该持仓在 Q2 2026 达到峰值 15,557 股,市值约 US$73K。 在 3 次申报中,CAXTON CORP 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 15,557 股、市值约 US$73K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 15.56K | $62.23K | 新进 |
| Q1 2026 | 15.56K | $64.25K | 持有 |
| Q2 2026 | 15.56K | $72.65K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 XFOR 与 13F 数据
XFOR(X4 PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 41 只申报持有 XFOR,申报仓位最大的包括:Bain Capital Life Sciences Investors, LLC (US$37.2M), PERCEPTIVE ADVISORS LLC (US$37.0M), Saturn V Capital Management LP (US$32.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 XFOR 的基金
- Bain Capital Life Sciences Investors, LLC 7.97M 股 · $37.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 7.93M 股 · $37.05M · Q2 2026
- Saturn V Capital Management LP 6.97M 股 · $32.57M · Q2 2026
- Empery Asset Management, LP 6.93M 股 · $32.37M · Q2 2026
- Deep Track Capital, LP 5.88M 股 · $27.45M · Q2 2026
- Kalehua Capital Management LLC 3.72M 股 · $17.39M · Q2 2026
- NEA Management Company, LLC 3.23M 股 · $15.10M · Q2 2026
- Rosalind Advisors, Inc. 3.21M 股 · $15.01M · Q2 2026
- Trails Edge Capital Partners, LP 2.57M 股 · $12.01M · Q2 2026
- BVF INC/IL 2.23M 股 · $10.43M · Q2 2026
- Venrock Adviser, LLC 1.93M 股 · $9.03M · Q2 2026
- Samsara BioCapital, LLC 1.40M 股 · $6.52M · Q2 2026
更多关于 CAXTON CORP
常见问题
How long has CAXTON CORP held XFOR?
CAXTON CORP has disclosed XFOR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is CAXTON CORP's current position in XFOR?
As of Q2 2026, CAXTON CORP holds 15.56K shares of XFOR (X4 PHARMACEUTICALS INC), valued at $72.65K, representing 3.92% of its reported portfolio and ranking #8.
Has CAXTON CORP been buying or selling XFOR?
In the latest 13F filing (Q2 2026), CAXTON CORP held unchanged its position in XFOR. The position peaked in Q2 2026 at 15.56K shares.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.